Enliven Therapeutics ELVN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $81.65M-4.9% | $85.86M+0.6% | $85.34M-3.4% | $88.37M+3.1% | $85.7M+6.1% | ||
| $34.14M+1.0% | $33.8M+25.5% | $26.93M+4.1% | $25.87M+5.4% | $24.56M+3.3% | ||
| $115.79M-3.2% | $119.66M+6.6% | $112.27M-1.7% | $114.24M+3.6% | $110.26M+5.5% | ||
| -$115.79M+3.2% | -$119.66M-6.6% | -$112.27M+1.7% | -$114.24M-3.6% | -$110.26M-5.5% | ||
| $17.01M+6.2% | $16.01M+6.0% | $15.11M+7.9% | $14M-5.6% | $14.84M-0.4% | ||
| $17.01M+6.6% | $15.96M+6.0% | $15.06M+7.4% | $14.03M-9.1% | $15.43M-0.6% | ||
| -$98.78M+4.7% | -$103.69M-6.7% | -$97.21M+3.0% | -$100.22M-5.7% | -$94.83M-6.5% | ||
| -$1.67+10.2% | -$1.86-1.1% | -$1.84+8.0% | -$2.00-4.2% | -$1.92-1.6% | ||
| -$115.59M+3.2% | -$119.4M-6.6% | -$111.97M+1.7% | -$113.93M-3.6% | -$109.95M-5.5% | ||
| -$115.79M+3.2% | -$119.66M-6.6% | -$112.27M+1.7% | -$114.24M-3.6% | -$110.26M-5.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Enliven Therapeutics profitable?
- Enliven Therapeutics is not currently profitable: it reported a net loss of $98.8M over the trailing twelve months.
- What is Enliven Therapeutics's earnings per share?
- Enliven Therapeutics's diluted EPS over the trailing twelve months is $-1.67.
- Where does Enliven Therapeutics's income statement data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.